Browse diseases

…cal responses at week (W) 60.Material and Methods patients with CHD treated with bulevirtide were included in the study. Bulevirtid…

…on, carrying substantial risks of liver fibrosis, cirrhosis and hepatocellular carcinoma. Fewer than 20% of patients receiving nucleos(t)ide analogues o…

…k in the progression from chronic liver injury to cirrhosis and hepatocellular carcinoma (HCC). Activated hepatic stellate cells (HSCs) play a central r…

…iver disease (MASLD)), viral hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma. These disorders arise from diverse aetiologies but converge on…

…Mortality and hospital admissions due to liver disease are increasing globally. 1–4 Patients with cirrhosis are at ris…

…ted variants when treatment fails.2 Consequently, patients with chronic hepatitis E who have not been cured by RBV therapy experience an unfavourab…

…Globally, liver disease accounts for more than 2 million deaths and is the 11th leading…

…tion arises from chronic liver disease, including cirrhosis and hepatocellular carcinoma, which predominantly affects young and middle-aged adults of bo…

…hronic hepatitis B (CHB) remains a major cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide, affecting over 250 million people. In the UK, …

…Primary biliary cholangitis (PBC) is a rare chronic autoimmune cholangiopathy that mainly a…

…pulmonary syndrome (HPS) is an under-recognised complication of chronic liver disease, affecting 10%–30% of patients with cirrhosis. It involves intr…

…earance is linked to substantially lower risks of cirrhosis and hepatocellular carcinoma, and it allows for safe discontinuation of NA therapy.1 The 202…